Deepak Gupta, Senior Resident at Medanta, shared on LinkedIn:
“Some clinical observations go beyond an individual case and offer valuable lessons for everyday practice.
Grateful to share our recent case report, published in Practical Radiation Oncology, exploring the possible association between axitinib and radiation-induced injury to adjacent normal liver tissue following SBRT.
A 65-year-old man with clear cell RCC, stable on axitinib for 7 years, developed a new right renal lesion and received SBRT (50 Gy in 5 fractions).
Weeks later, he developed focal hepatonecrosis in the adjacent liver segment, in the intermediate-dose region (~25 Gy).
Key takeaways:
- Axitinib may have a possible radiosensitizing effect on normal tissue
- A 3-month drug holiday, with pentoxifylline and vitamin E, led to complete symptom and imaging resolution
- Axitinib was safely restarted, with no avid lesions on follow-up PET-CT
Deeply thankful to my Seniors Shyam S. Bisht, Dheeraj Gautam , Satyapal Kataria, Sorun Shishak, Deepak Gupta , Susovan Banerjee, Kushal Narang, Mayur Mayank, Tejinder Kataria and to the entire Medanta team for their support.”
Title: Exacerbation of Focal Hepatotoxicity With Axitinib After Stereotactic Body Radiation Therapy to Malignant Renal Mass in Close Proximity to Liver and Resolution After Short-Term Drug Holiday: Possible Radiosensitization Effect
Authors: Shyam Singh Bisht, Ayushee Saini, Dheeraj Gautam, Satyapal P. Kataria, Sorun Shishak, Deepak Gupta, Susovan Banerjee, Kushal Narang, Mayur Mayank, Tejinder Kataria.
Deepak Gupta, Director, Radiation Oncology of Medanta Hospital, added:
“Great work by Ayushee Saini and Our team at Medanta Hospital (Gurgaon).
A useful reminder to watch for TKI-related radiosensitization when planning SBRT near the liver.”
You can also read: Aadil Najeed: Can Adaptive SBRT Improve Local Control After Chemoradiotherapy?